Metabolic Disorders/Obesity Is a Primary Risk Factor in Hidradenitis Suppurativa: An Immunohistochemical Real-World Approach

被引:21
|
作者
Kaleta, Katarzyna P. [1 ,2 ,3 ,4 ,5 ,6 ]
Nikolakis, Georgios [1 ,2 ,3 ,4 ,5 ,7 ]
Hossini, Amir M. [1 ,2 ,3 ,4 ,5 ]
Balthasar, Ottfried [1 ,2 ,3 ,4 ,5 ,8 ]
Almansouri, Daifallah [1 ,2 ,3 ,4 ,5 ]
Vaiopoulos, Aristeidis [1 ,2 ,3 ,4 ,5 ,7 ]
Knolle, Jurgen [8 ]
Boguslawska, Anna [9 ]
Wojas-Pelc, Anna [6 ]
Zouboulis, Christos C. [1 ,2 ,3 ,4 ,5 ,7 ]
机构
[1] Brandenburg Med Sch Theodor Fontane, Dessau Med Ctr, Dept Dermatol, Dessau, Germany
[2] Brandenburg Med Sch Theodor Fontane, Dessau Med Ctr, Dept Venereol, Dessau, Germany
[3] Brandenburg Med Sch Theodor Fontane, Dessau Med Ctr, Dept Allergol, Dessau, Germany
[4] Brandenburg Med Sch Theodor Fontane, Dessau Med Ctr, Dept Immunol, Dessau, Germany
[5] Fac Hlth Sci Brandenburg, Dessau, Germany
[6] Jagiellonian Univ Med Coll, Dept Dermatol, Krakow, Poland
[7] European Hidradenitis Suppurat Fdn eV, Dessau, Germany
[8] Dessau Med Ctr, Inst Pathol, Dessau, Germany
[9] Jagiellonian Univ Med Coll, Paediat Inst, Dept Paediat & Adolescence Endocrinol, Krakow, Poland
关键词
Smoking; Risk factors; Hidradenitis suppurativa; Acne inversa; Obesity; Interleukin-17; ARYL-HYDROCARBON RECEPTOR; SZ95; SEBOCYTES; LIPID-SYNTHESIS; SMOKING; SKIN; PREVALENCE; EXPRESSION; COMORBIDITIES; SEVERITY; OBESITY;
D O I
10.1159/000517017
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Hidradenitis suppurativa (HS) is an inflammatory, potentially scarring disease of the hair follicle, affecting the apocrine gland-bearing skin areas. The major comorbid disorders associated with the occurrence or the aggravation of the disease are obesity and smoking. Numerous efforts to dissociate these factors led to controversial results. Objectives: To assess the importance of metabolic disorders/obesity, smoking/environmental toxins, and inflammation in HS by utilizing the differential expression of major relevant protein markers in lesional skin of obese/smoking versus non-obese/non-smoking HS patients. Methods: Lesional skin specimens deriving from two groups of HS patients (BMI >30 and smokers, n = 12 vs. BMI <30 and non-smokers, n = 10) were stained with antibodies raised against irisin, PPAR gamma, and IGF-1R, which correlate with metabolic disorders/obesity, EGFR and AhR, associated with smoking, and IL-17, IL-17R, and S100A8, as markers of inflammation. Results: Metabolic disorders/obesity-related markers exhibited marked differential expression between the two groups, while smoking-associated markers a limited one. IL-17R expression was stronger in obese/smokers, and S100A8 staining exhibited intense strong immunoreactivity in both groups without significant difference. Conclusions: The notion that obesity plays a role in HS development appears to be supported by the prominent regulation of the associated lesional biomarkers. Tobacco smoking might contribute less to HS than previously suspected.
引用
收藏
页码:251 / 259
页数:9
相关论文
共 50 条
  • [31] Unmet clinical needs, burden of disease and treatment patterns in hidradenitis suppurativa: Real-world experience from Spain
    Vilarrasa, Eva
    Molina-Leyva, Alejandro
    Martin, Victor
    Coak, Emily
    Truman, Isabel
    Wallinger, Hayley
    Richardson, Craig
    Martorell, Antonio
    JEADV CLINICAL PRACTICE, 2024, 3 (01): : 347 - 357
  • [32] Risk of hemorrhagic and ischemic stroke subsequent to diagnosis for hidradenitis suppurativa: Real-world data from a large urban Midwestern US patient population
    Parker, Jennifer
    Gwillim, Eran
    Ali, Yasmeen
    Pease, David Randall
    Laumann, Anne E.
    West, Dennis P.
    Nardone, Beatrice
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB187 - AB187
  • [33] Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study
    Gulliver, W.
    Alavi, A.
    Wiseman, M. C.
    Gooderham, M. J.
    Rao, J.
    Alam, M. S.
    Papp, K. A.
    Desjardins, O.
    Jean, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (12) : 2431 - 2439
  • [34] Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study
    Kozera, Emily
    Flora, Akshay
    Frew, John W.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (06) : 1440 - 1442
  • [35] Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US
    Ingram, J. R.
    Bettoli, V
    Espy, J., I
    Kokolakis, G.
    Martorell, A.
    Villani, A. P.
    Wallinger, H.
    Coak, E.
    Kasparek, T.
    Muscianisi, E.
    Richardson, C.
    Kimball, A. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (09) : 1597 - 1605
  • [36] Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study
    Haselgruber, Sofia
    Fernandez-Crehuet-Serrano, Pablo
    Fernandez-Ballesteros, Maria Dolores
    Padial-Gomez, Alicia
    Hernandez-Rodriguez, Juan Carlos
    Ortiz-alvarez, Juan
    Navarro-Guillamon, Pedro
    Membrive-Jimenez, Cristina
    Cuenca-Barrales, Carlos
    Molina-Leyva, Alejandro
    DERMATOLOGY AND THERAPY, 2024, 14 (07) : 1875 - 1890
  • [37] Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa; a randomized controlled trial in a real-world setting (#90)
    Aarts, Pim
    van Huijstee, Johanna C.
    van der Zee, Hessel H.
    van Doorn, Martijn B.
    van Straalen, Kelsey R.
    Prens, Errol P.
    EXPERIMENTAL DERMATOLOGY, 2023, 32 : 29 - 30
  • [38] Risk of ischemic heart disease in patients with hidradenitis suppurativa: Analysis of real-world data within a large, urban, Midwestern US dermatology patient population
    Gwillim, Eran C.
    Parker, Jennifer J.
    Figueiredo, Anna C.
    Pontes, David
    Laumann, Anne E.
    West, Dennis P.
    Nardone, Beatrice
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB143 - AB143
  • [39] Management of cardiovascular risk in primary prevention: real-world data
    Danchin, N.
    Puymirat, E.
    Vedrenne, G.
    Durand, E.
    ARCHIVES OF CARDIOVASCULAR DISEASES SUPPLEMENTS, 2012, 4 (04) : 279 - 283
  • [40] Application of the CADILLAC risk core in the "real-world" of primary angioplasty
    Assali, Abid
    Ben-Dor, Itsik
    Brosh, David
    Teplitsky, Igal
    Solodky, Alejandro
    Fuchs, Shmuel
    Kornowski, Ran
    AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (8A): : 69M - 69M